|Bid||276.99 x 1100|
|Ask||277.02 x 1000|
|Day's Range||271.56 - 279.89|
|52 Week Range||226.02 - 309.99|
|Beta (3Y Monthly)||1.24|
|PE Ratio (TTM)||64.54|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||1.36 (0.45%)|
|1y Target Est||322.50|
Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.
Higher Invisalign case volume, solid show by Clear Aligner segment and anticipated sturdy growth at Scanner and Service business are likely to support Align Technology (ALGN) in Q1. However, operating expenses are likely to act as dampeners.
WAYNE, Pa., April 18, 2019 -- Teleflex Incorporated (NYSE: TFX) announced today that financial results for the first quarter 2019 will be released before market open on.
Teleflex Inc NYSE:TFXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for TFX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding TFX are favorable with net inflows of $72.54 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Industrials sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
While the market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, declining oil prices and the trade war with China, many smart money investors kept their optimism regarding the current bull run in the fourth quarter, while still hedging many of their long positions. However, […]
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Measuring Teleflex Incorporated's (NYSE:TFX) track record of past performance is an insightful exercise for investors. It ena...
Consensus expectations for Teleflex Incorporated (NYSE: TFX ) imply an improvement in revenue growth from an estimated 6.5 percent in 2019 to 7.2 percent in 2020, according to Raymond James. New product ...
Teleflex Incorporated (TFX), a leading global provider of medical technologies for critical care and surgery, has announced the publication of its inaugural corporate social responsibility report, The JOIN Impact Report. The report outlines the company’s responsibility commitments and activities in the areas of people, the environment and business progress. “Our employees truly make the greatest impact,” said Liam Kelly, President and CEO.
Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”) and Teleflex Incorporated (TFX), a leading global provider of medical technologies for critical care and surgery, announce a collaboration under which Teleflex’s market-leading polymer ligation technology will be integrated into Titan’s development-stage, single-port robotic surgery system. Teleflex’s Weck® Hem-o-lok® polymer ligation system is a proven ligation technology for vessel sealing with enhanced clip security features that surgeons have used in millions of patients worldwide.
A study by TeleFlex (TFX) sheds light on the real-world retrospective data on 30 men suffering urinary retention treated with the UroLift System.
Findings Presented at European Association of Urology Show Consistent Positive Results for Minimally Invasive UroLift System Treatment
WAYNE, Pa., March 21, 2019 -- Teleflex Incorporated (NYSE:TFX) today announced that multiple studies were presented at the 2019 European Association of Urology (EAU) meeting in.
The UroLift® System for Benign Prostatic Hyperplasia is being showcased at the professional Barcelona-held urology event from tomorrow on Booth F43. A poster presentation at Green Area, Room 20, will highlight the use of the treatment in men with catheter dependent urinary retention.
Let's talk about the popular Teleflex Incorporated (NYSE:TFX). The company's shares saw a significant share price rise of over 20% in the past couple of months on the NYSE. AsRead More...
NEW YORK, Feb. 26, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Liam Kelly, President and Chief Executive Officer, Teleflex Incorporated , is scheduled to speak at Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida, on Tuesday, March 12, 2019 at 8:00 am .
Inc. on Thursday reported a fourth-quarter profit after posting a loss in the year-earlier period, partly due to a lower tax rate. Excluding items, Teleflex reported an adjusted profit of $2.77 a share for the quarter, compared with $2.44 a share last year and analysts’ forecasts of $2.75. Teleflex said it expects 2019 revenues to increase by between 5% and 6%, while full-year per-share earnings are seen between $6.90 and $7.05.
Teleflex (TFX) delivered earnings and revenue surprises of -0.36% and 0.25%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?